Key result
Recombinant human soluble thrombomodulin attenuated clot growth and clot-induced thrombin generation in human plasma by activating protein C.
Why the study?
Does recombinant human soluble thrombomodulin (rhs-TM) attenuate clot-induced coagulation in human plasma?
Population
Human plasma (in vitro model)
Comparison
Recombinant human soluble thrombomodulin (rhs-TM) vs Argatroban, heparin, Fragmin, and control
Design
Preclinical
Authors
Loading...
Hypothesis-generating for rhs-TM in human plasma; leaves open translation to clinical thrombosis management.
Does recombinant human soluble thrombomodulin (rhs-TM) attenuate clot-induced coagulation in human plasma?
Recombinant human soluble thrombomodulin attenuates clot growth in vitro by activating protein C and inhibiting further thrombin generation.
Suzuki et al. (1998) studied Clot-induced coagulation. Recombinant human soluble thrombomodulin (rhsTM) vs. Argatroban, heparin, and low molecular weight heparin was evaluated on Clot-induced thrombin generation and clot growth. Recombinant human soluble thrombomodulin attenuated clot growth and clot-induced thrombin generation in human plasma by activating protein C.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: